Call for Applications: Join the NMD4C’s Basic Science Trainee Committee
We are excited to share an opportunity for Canadian neuromuscular trainees to help shape NMD4C’s basic science trainee strategy by joining the NMD4C Basic Science Trainee Committee (BSTC)! Committee members will represent the interests of neuromuscular trainees, provide strategic input on NMD4C trainee opportunities, organize events/workshops, and help build a supportive community while developing their own leadership skills and professional network. The BSTC Terms of Reference provides more information about the committee roles and responsibilities!
Available Positions: Chaired by Dr. Jean-Philippe Leduc-Gaudet, the committee offers leadership positions (co-chair and secretary) as well as general members. General members will contribute to discussions, participate in decision-making, and lead specific initiatives. We’re looking for trainees with a collaborative spirit, strong communication skills, and a commitment to advancing neuromuscular research training.
Applications for the BSTC are now closed.
For questions or additional information, please contact network manager Erin Beattie at
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.